3’-methoxy-[1,1’-biphenyl]-2,3-diamine | 1035390-04-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3’-methoxy-[1,1’-biphenyl]-2,3-diamine
• 英文别名: 3'-methoxy-biphenyl-2,3-diamine；3-(3-Methoxyphenyl)benzene-1,2-diamine
• CAS: 1035390-04-5
• 化学式: C₁₃H₁₄N₂O
• 分子量: 214.267
• InChiKey: ADORISSUWLMVPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3‘-methoxy-2-nitro-[1,1‘-biphenyl]-3-amine 在 sodium sulfide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以42.1%的产率得到3’-methoxy-[1,1’-biphenyl]-2,3-diamine
  参考文献：
  名称：

  [EN] 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF
  [FR] 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  4-氮杂吲唑化合物用于治疗各种疾病和病理已被披露。更具体地，本发明涉及使用4-氮杂吲唑化合物或其类似物，治疗由Wnt途径信号激活所特征的疾病（例如，癌症，异常细胞增殖，血管生成，纤维化疾病，骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。

  公开号：

  WO2017023989A1

文献信息

• SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY
  申请人：Woodhead Steven John

  公开号：US20100093748A1

  公开（公告）日：2010-04-15

  The invention provides PKA and PKB kinase-inhibiting compounds of the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein E is a five membered heteroaryl ring containing 1, 2, 3 or 4 heteroatoms selected from O, N and S provided that no more than 1 heteroatom may be other than N; q and r are each is 0 or 1; provided that q+r is 1 or 2; T is N or a group CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); Q 3 is a bond or a saturated C 1-3 hydrocarbon linker group optionally substituted by fluorine and hydroxy; G is NR 2 R 3 , CN or OH; m and n are each 0 or 1, provided that m+n is 1 or 2, and provided also that m or n are each 0 when the adjacent ring member of ring E is S or O; R 1a and R 1b are the same or different and each is hydrogen or a substituent R 10 ; or R 1a and R 1b together with the carbon atoms or heteroatoms to which they are attached form a 5 or 6-membered aryl or heteroaryl ring, wherein the aryl or heteroaryl rings are optionally substituted by one or more substituents R 10 ; and R 2 , R 3 , R 4 , R 5 , R 7 , R 6 , R 8 , and R 10 are as defined in the claims.

  本发明提供了式(I)的PKA和PKB激酶抑制化合物，或其盐、溶剂化物、互变异构体或N-氧化物，其中E是一个五元杂环芳基环，包含1、2、3或4个从O、N和S中选择的杂原子，但不得多于1个杂原子不是N；q和r各自为0或1；前提是q+r为1或2；T为N或CR5基团；J1-J2为N═C(R6)、(R7)C═N、(R8)N—C(O)、(R8)2C—C(O)、N═N或(R7)C═C(R6)；Q3为键或饱和的C1-3烃基连接基团，可选地被氟和羟基取代；G为NR2R3、CN或OH；m和n各自为0或1，前提是m+n为1或2，且当环E的相邻环成员为S或O时，m或n各自为0；R1a和R1b相同或不同，各自为氢或取代基R10；或R1a和R1b与它们所连接的碳原子或杂原子一起形成一个5或6元芳基或杂芳基环，其中芳基或杂芳基环可选地被一个或多个取代基R10取代；R2、R3、R4、R5、R7、R6、R8和R10如权利要求所定义。
• 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
  申请人：Samumed, LLC

  公开号：US10392383B2

  公开（公告）日：2019-08-27

  4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明公开了用于治疗各种疾病和病理的 4-氮杂吲唑化合物。更具体地说，本发明涉及 4-氮杂吲唑化合物或其类似物在治疗以 Wnt 通路信号激活为特征的疾病（如癌症、异常细胞增殖、血管生成、纤维化疾病、骨或软骨疾病以及骨关节病）中的用途、癌症、异常细胞增殖、血管生成、纤维化疾病、骨或软骨疾病和骨关节炎）、调节由 Wnt 通路信号介导的细胞事件以及由于 Wnt 通路和/或一种或多种 Wnt 信号元件的突变或失调引起的遗传性疾病和神经系统病症/紊乱/疾病。此外，还提供了治疗 Wnt 相关疾病状态的方法。
• [EN] SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY<br/>[FR] PIPÉRIDINES SUBSTITUÉES AYANT UNE ACTIVITÉ INHIBANT LA PROTÉINE KINASE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2008075109A1

  公开（公告）日：2008-06-26

  [EN] The invention provides PKA and PKB kinase-inhibiting compounds of the formula (I); or salts, solvates, tautomers or N-oxides thereof, wherein E is a five membered heteroaryl ring containing 1, 2, 3 or 4 heteroatoms selected from O, N and S provided that no more than 1 heteroatom may be other than N; q and r are each is 0 or 1; provided that q+r is 1 or 2; T is N or a group CR⁵; J¹-J² is N=C(R⁶), (R⁷)C=N, (R⁸)N- C(O), (R⁸)₂C-C(O), N=N or (R⁷)C=C(R⁶); Q³ is a bond or a saturated C_1-3 hydrocarbon linker group optionally substituted by fluorine and hydroxy; G is NR²R³, CN or OH; m and n are each 0 or 1, provided that m+n is 1 or 2, and provided also that m or n are each 0 when the adjacent ring member of ring E is S or O; R^1a and R^1b are the same or different and each is hydrogen or a substituent R¹⁰; or R^1a and R^1b together with the carbon atoms or heteroatoms to which they are attached form a 5 or 6-membered aryl or heteroaryl ring, wherein the aryl or heteroaryl rings are optionally substituted by one or more substituents R¹⁰; and R², R³, R⁴, R⁵, R⁷, R⁶, R⁸, and R¹⁰ are as defined in the claims.
  [FR] L'invention concerne des composés inhibant PKA et PKB kinase de formule (I), oo des sels, des solvates, des tautomères ou des N-oxydes de celle-ci, formule dans laquelle E représente un noyau hétéroaryle à cinq éléments contenant 1, 2, 3 ou 4 hétéroatomes sélectionnés parmi O, N et S à condition que pas plus d'un hétéroatome puisse être différent de N; q et r représentent chacun 0 ou 1, à condition que q+r soit égal à 1 ou 2; T représente N ou un groupe CR⁵; J¹-J² is N=C(R⁶), (R⁷)C=N, (R⁸)N- C(O), (R⁸)₂C-C(O), N=N ou (R⁷)C=C(R⁶); Q³ représente une liaison ou un groupe lieur d'hydrocarbone C₁
• [EN] 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017023989A1

  公开（公告）日：2017-02-09

  4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  4-氮杂吲唑化合物用于治疗各种疾病和病理已被披露。更具体地，本发明涉及使用4-氮杂吲唑化合物或其类似物，治疗由Wnt途径信号激活所特征的疾病（例如，癌症，异常细胞增殖，血管生成，纤维化疾病，骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。